- |||||||||| hydroxychloroquine / Generic mfg., ivermectin oral / Generic mfg.
Journal: Chronic Kidney Disease and COVID-19: Outcomes of hospitalised adults from a tertiary care centre in North India. (Pubmed Central) - Feb 17, 2022 Oxygen therapy was needed in 62.9%, and medications used were hydroxychloroquine in 84.5%, azithromycin in 21.6%, ivermectin in 82.6%, steroids in 63.8% and Low molecular weight heparin in 59.2%...The overall mortality was 24.4%, with similar mortality rates in both groups (P = 0.709) and 20.7% needed ICU transfer. Adults with CKD especially on haemodialysis, are prone to more severe COVID-19 infection and take a longer time for viral clearance (>2 weeks); the mortality too is higher in these patients.
- |||||||||| ivermectin oral / Generic mfg.
Journal: US Insurer Spending on Ivermectin Prescriptions for COVID-19. (Pubmed Central) - Feb 15, 2022 These results suggest that slash and clear may offer an inexpensive and effective way to augment ivermectin distribution in the effort to eliminate onchocerciasis in Africa. No abstract available
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: Repurposing the drug, ivermectin, in COVID-19: toxicological points of view. (Pubmed Central) - Feb 15, 2022 Many pre-existing medications such as tocilizumab, ivermectin, colchicine, interferon, and steroids have been evaluated for being repurposed to use for the treatment of COVID-19...Based on the current dose recommendation, ivermectin appears to be safe with minimum side effects. However, serious questions remain about the effectiveness of this drug in the treatment of patients with COVID-19.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: Current status of therapeutic alternatives for COVID-19: A narrative review. (Pubmed Central) - Feb 12, 2022 The discussion includes antiviral agents (hydroxychloroquine, lopinavir/ritonavir, remdesivir, favipiravir and ivermectin) and, various immunomodulatory drugs (corticosteroids, tocilizumab, baricitinib, and IL-1 inhibitors). Other investigational therapies including darunavir/cobicistat, umifenovir, sofosbuvir/daclatasvir, sofobuvir/ledipasvir, ribavirin, nitazoxanide and interferon-based regimens were not evaluated due to insufficient data on the efficacy and safety of these agents.
- |||||||||| ivermectin oral / Generic mfg.
Clinical guideline, Retrospective data, Review, Journal: Expression of Concern for Bryant a, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Am J Ther. 2021;28(4): e434-e460. (Pubmed Central) - Feb 11, 2022 Other investigational therapies including darunavir/cobicistat, umifenovir, sofosbuvir/daclatasvir, sofobuvir/ledipasvir, ribavirin, nitazoxanide and interferon-based regimens were not evaluated due to insufficient data on the efficacy and safety of these agents. No abstract available
- |||||||||| moxidectin / Generic mfg.
Enrollment closed, Enrollment change: Moxidectin for LF, Cote d'Ivoire (DOLF) (clinicaltrials.gov) - Feb 11, 2022 P3, N=164, Active, not recruiting, No abstract available Enrolling by invitation --> Active, not recruiting | N=250 --> 164
- |||||||||| albendazole / Generic mfg.
Enrollment closed, Trial completion date, Combination therapy: DOLF IDA/Oncho: Safety and Efficacy of IDA for Onchocerciasis (clinicaltrials.gov) - Feb 11, 2022 P2, N=201, Active, not recruiting, Enrolling by invitation --> Completed Enrolling by invitation --> Active, not recruiting | Trial completion date: Jan 2022 --> Jan 2023
- |||||||||| etesevimab (JS016) / Chinese Academy of Sciences, Shanghai Junshi Biosci, Eli Lilly
Clinical, Review, Journal: Interventions in an Ambulatory Setting to Prevent Progression to Severe Disease in Patients With COVID-19: A Systematic Review. (Pubmed Central) - Feb 10, 2022 Based on published data, insufficient evidence of effect was found for bamlanivimab (monotherapy), casirivimab plus imdevimab, ivermectin (monotherapy), nitazoxanide, and peginterferon lambda...Recent trials have shown promising results for a number of pharmacological agents to treat COVID-19 in the ambulatory setting. However, larger, more robust trials are needed to support the routine use of these agents outside of monitored clinical trials.
|